XSHE
002019
Market cap1.72bUSD
Oct 09, Last price
9.66CNY
1D
2.33%
1Q
-2.13%
Jan 2017
-36.82%
IPO
704.19%
Name
Yifan Pharmaceutical Co Ltd
Chart & performance
P/E
29.23
P/S
2.29
EPS
0.33
Div yield, %
1.06%
Shrs. gr., 5y
-0.12%
Rev. gr., 5y
-1.01%
Revenues
5.13b
-0.52%
Net income
402m
+4.16%
CFO
458m
-28.46%
Dividend
May 29, 20260.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yifan Pharmaceutical Co., Ltd. engages in the research, development, production, sale of pharmaceutical products, active pharmaceutical ingredients and polymer materials. It provides blood tumors, gynecology, pediatrics, skin, orthopedic drugs, phosphate buffered saline, polyvinyl butyral products, vitamin B5 and original B5. The company was founded on November 10, 2000 and is headquartered in Hangzhou, China.
Key people
Liping Qian
Executive President · since 2025
Feng Wang
Executive President · since 2025
Yuhong Geng
Executive President · since 2025
Hang Lin
Vice President, Director · since 2022
Xianfeng Cheng
Chairman of the Board, President · since 2022
Deqi Feng
Vice President, Secretary of the Board, Director · since 2022
Benyu Zhou
Staff Elected Director · since 2025
Independent Director · since 2020
Yuhong Zeng
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||